Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1099/jgv.0.001599 http://scihub22266oqcxt.onion/10.1099/jgv.0.001599 33961540!8295914!33961540     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Gen+Virol 2021 ; 102 (5): ä Nephropedia Template TP {{tp|p=33961540|t=2021. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease |pdf=|usr=}}{{33961540}} gab.com Text Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease JO: J Gen Virol http://www.kidney.de/pget.php?&tw=1&pmid=33961540 #FOAvip SARS-CoV-2 is the causative agent of COVID-19 and human infections have resulted in a global health emergency. Small animal models that reproduce key elements of SARS-CoV-2 human infections are needed to rigorously screen candidate drugs to mitigate severe disease and prevent the spread of SARS-CoV-2. We and others have reported that transgenic mice expressing the human angiotensin-converting enzyme 2 (hACE2) viral receptor under the control of the Keratin 18 (K18) promoter develop severe and lethal respiratory disease subsequent to SARS-CoV-2 intranasal challenge. Here we report that some infected mice that survive challenge have residual pulmonary damages and persistent brain infection on day 28 post-infection despite the presence of anti-SARS-COV-2 neutralizing antibodies. Because of the hypersensitivity of K18-hACE2 mice to SARS-CoV-2 and the propensity of virus to infect the brain, we sought to determine if anti-infective biologics could protect against disease in this model system. We demonstrate that anti-SARS-CoV-2 human convalescent plasma protects K18-hACE2 against severe disease. All control mice succumbed to disease by day 7; however, all treated mice survived infection without observable signs of disease. In marked contrast to control mice, viral antigen and lesions were reduced or absent from lungs and absent in brains of antibody-treated mice. Our findings support the use of K18-hACE2 mice for protective efficacy studies of anti-SARS-CoV-2 medical countermeasures (MCMs). They also support the use of this system to study SARS-CoV-2 persistence and host recovery. Twit Text FOAVip Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease ????J Gen Virol http://www.kidney.de/pget.php?&tw=1&pmid=33961540 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33961540 #FOAvip English Wikipedia <ref>{{Cite pmid|33961540}}</ref> Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease #MMPMID33961540 Golden JW; Zeng X; Cline CR; Garrison AR; White LE; Fitzpatrick CJ; Kwilas SA; Bowling PA; Fiallos JO; Moore JL; Sifford WB; Ricks KM; Mucker EM; Smith JM; Hooper JW J Gen Virol 2021[May]; 102 (5): ä PMID33961540show ga SARS-CoV-2 is the causative agent of COVID-19 and human infections have resulted in a global health emergency. Small animal models that reproduce key elements of SARS-CoV-2 human infections are needed to rigorously screen candidate drugs to mitigate severe disease and prevent the spread of SARS-CoV-2. We and others have reported that transgenic mice expressing the human angiotensin-converting enzyme 2 (hACE2) viral receptor under the control of the Keratin 18 (K18) promoter develop severe and lethal respiratory disease subsequent to SARS-CoV-2 intranasal challenge. Here we report that some infected mice that survive challenge have residual pulmonary damages and persistent brain infection on day 28 post-infection despite the presence of anti-SARS-COV-2 neutralizing antibodies. Because of the hypersensitivity of K18-hACE2 mice to SARS-CoV-2 and the propensity of virus to infect the brain, we sought to determine if anti-infective biologics could protect against disease in this model system. We demonstrate that anti-SARS-CoV-2 human convalescent plasma protects K18-hACE2 against severe disease. All control mice succumbed to disease by day 7; however, all treated mice survived infection without observable signs of disease. In marked contrast to control mice, viral antigen and lesions were reduced or absent from lungs and absent in brains of antibody-treated mice. Our findings support the use of K18-hACE2 mice for protective efficacy studies of anti-SARS-CoV-2 medical countermeasures (MCMs). They also support the use of this system to study SARS-CoV-2 persistence and host recovery. |Acute Lung Injury/prevention & control/virology[MESH] |Angiotensin-Converting Enzyme 2/genetics/metabolism[MESH] |Animals[MESH] |Antibodies, Neutralizing/blood/immunology[MESH] |Antibodies, Viral/blood/immunology[MESH] |Brain/pathology/virology[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/immunology/pathology/*therapy/virology[MESH] |Disease Models, Animal[MESH] |Female[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Lung/pathology/virology[MESH] |Male[MESH] |Mice[MESH] |Mice, Inbred C57BL[MESH] |Mice, Transgenic[MESH] |Receptors, Coronavirus/genetics/metabolism[MESH] |SARS-CoV-2/immunology/isolation & purification/physiology[MESH] |Severity of Illness Index[MESH] |Viral Load[MESH]Human convalescent plasma protects K18-hACE2 mice against severe respi(epmc).pdf DeepDyve Pubget Overpricing